FDA slaps a full clin­i­cal hold on Al­co­bra’s trou­bled lead drug for AD­HD, Frag­ile X

Fol­low­ing a se­ries of clin­i­cal set­backs and mis­steps, Al­co­bra $AD­HD says its lead drug MDX has been put on a full clin­i­cal hold by the FDA “due to ad­verse neu­ro­log­i­cal find­ings in a pre-clin­i­cal study.”

The hold will stop its on­go­ing Phase III study in adult pa­tients with AD­HD, ac­cord­ing to the Is­raeli biotech, which re­port­ed at the end of Au­gust that it had re­cruit­ed 474 pa­tients for the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.